Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATIANA: TPEx + Avelumab in Head and Neck Cancer
NCT06640725Phase 2Recruiting
- Sponsor
- GORTEC
- Start
- Jan 2025
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by GORTEC. Primary endpoint: Overall Survival at 3 years. Started Jan 2025; status: recruiting.
02
Drugs
avelumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT06640725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640725.